View Rule
| View EO 12866 Meetings | Printer-Friendly Version Download RIN Data in XML |
| SSA | RIN: 0960-AH43 | Publication ID: Fall 2014 |
| Title: Revised Medical Criteria for Evaluating Cancer (Malignant Neoplastic Diseases) (3757F) | |
|
Abstract:
Sections 13.00 and 113.00, Malignant Neoplastic Diseases, of appendix 1 to subpart P of our regulations describe malignant neoplastic diseases that we consider severe enough to prevent an individual from doing any gainful activity or that cause marked and severe functional limitations for a child claiming SSI payments under title XVI. We will revise these sections to ensure that the medical evaluation criteria are up-to-date and consistent with the latest advances in medical knowledge and treatment. |
|
| Agency: Social Security Administration(SSA) | Priority: Other Significant |
| RIN Status: Previously published in the Unified Agenda | Agenda Stage of Rulemaking: Final Rule Stage |
| Major: No | Unfunded Mandates: No |
| CFR Citation: 20 CFR 404.1500, app 1 | |
| Legal Authority: 42 USC 402 42 USC 405(a) 42 USC 405(b) 42 USC 405(d) to 405(h) 42 USC 405(h) 42 USC 416(i) 42 USC 421(a) 42 USC 421(i) 42 USC 423 42 USC 902(a)(5) 42 USC 1381a 42 USC 1382c 42 USC 1383 42 USC 1383b | |
|
Legal Deadline:
None |
||||||||||||
|
Statement of Need: These final regulations are necessary to update the Malignant Neoplastic Diseases listings to reflect advances in medical knowledge, treatment, and methods of evaluating malignant neoplastic diseases. The changes will ensure that determinations of disability have a sound medical basis, that claimants receive equal treatment through the use of specific criteria, and that people who are disabled can be readily identified and awarded benefits if all other factors of entitlement or eligibility are met. |
||||||||||||
|
Summary of the Legal Basis: Administrative--not required by statute or court order. |
||||||||||||
|
Alternatives: We considered not revising the listings and continuing to use our current criteria. However, we believe that these revisions are preferable because of the medical advances that have been made in treating and evaluating these malignant neoplastic diseases and because of our adjudicative experience. |
||||||||||||
|
Anticipated Costs and Benefits: Estimated costs--low. |
||||||||||||
|
Risks: None. |
||||||||||||
Timetable:
|
| Regulatory Flexibility Analysis Required: No | Government Levels Affected: None |
| Small Entities Affected: No | Federalism: No |
| Included in the Regulatory Plan: Yes | |
| Public Comment URL: www.regulations.gov | |
| RIN Data Printed in the FR: No | |
|
Agency Contact: Cheryl A. Williams Director Social Security Administration Office of Medical Policy, 6401 Security Boulevard, Baltimore, MD 21235-6401 Phone:410 965-1020 Email: cheryl.a.williams@ssa.gov Mark Kuhn Social Insurance Specialist Social Security Administration Office of Medical Listings Improvement, 6401 Security Boulevard, Baltimore, MD 21235-6401 Phone:410 966-6109 Brian Rudick Social Insurance Specialist, Regulations Writer Social Security Administration Office of Regulations and Reports Clearance, 6401 Security Boulevard, Baltimore, MD 21235-6401 Phone:410 965-1483 Email: brian.rudick@ssa.gov |
|
An official website of the United States government




